ABOUT US

2008	◊ TGA (Australia) approval for the Solid Dosage, Liquid Orals and Creams & Ointments Dosage forms at GOA Plant I.
	◊ Launch of OncoSpera - a Oncology marketing division.
	◊ First shipment of Diclofenac Ophthalmic solution shipped to USA against an approved ANDA.
	◊ Successfully faced Slovenia audit for the Solid Oral Dosage forms at Baddi Plant.
	◊ MCC (South Africa) approval for the Solid Dosage facility at GOA Plant I and for the Sterile facility at Goa Plant II.
2007	◊ Joint Venture with Amneal Pharmaceuticals Inc., a US based company to develop and market ophthalmic products in the US market.
	◊ ANVISA (Brazil) approval for the Solid Dosage facility at GOA Plant I.
	◊ Commencement of exports to the regulated US markets.
	◊ Launch of Warren-Excel and Spera - two specialty marketing divisions.
2006	◊ US-FDA approval for Ophthalmic facility, Plant-II in GOA.
	◊ Contract signed for supply of 18 generic products to German Market.
	◊ 2 ANDAs filed with USFDA.
	◊ Commencement of liquid manufacturing facility at Baddi, Himachal Pradesh.
	◊ New R&D Centre at Rabale, near Mumbai becomes functional.
	◊ Solid Dosage facility at Goa Plant I re-inspected & approved by UK-MHRA.
	◊ UK-MHRA approval for Creams & Ointments facility.
	◊ Darmstadt-Germany approves our Goa facility for Solid Dosage manufacturing.
	◊ Acquisition of LaNOVA Chem Pvt. Ltd. with its brand new API manufacturing facility of international standards.
	◊ Launch of Surge - a specialty marketing division.
2005	◊ First ANDA filed on the basis of Exhibit batches manufactured in our sterile facility in Goa.
	◊ Development Contracts for injectable products signed with a US Company.
	◊ Tablet capacity doubled by commissioning an extended facility in the existing UK-MHRA approved plant.
	◊ Shares of the Company listed on BSE and NSE.
2004	◊ First Contract for Development services with US Company.
	◊ Karvol brand acquisition from Solvay Pharmaceuticals Pvt. Ltd.
	◊ Four Patent applications filed.
	◊ Company jumps five ranks in two yrs in the ORG-IMS Retail Audit.
2003	◊ UK-MHRA approval for the Solid Dosage facility at Plant I.
	◊ Exports to regulated markets commence.
	◊ First contract for Dossier Development with European company.
	◊ Domestic Marketing makes a foray into the lifestyle segment.
2002	◊ Launch of Radius - the super specialty marketing division.
	◊ State-of-the-art sterile facility, Plant II commissioned at Verna Goa.
1999	◊ New Corporate Office at Indoco House.
	◊ Acquisition of Warren, Company makes presence in Ophthalmic &  Dental Segments.
1997	◊ Commencement of production in Goa Plant I.
1993	◊ R&D recognized by DSIR.